Shortly after SunPharma received USFDA approval for anti-depressant
tablets<http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/Sun-Pharma-receives-USFDA-approval-for-anti-depressant-tablets/articleshow/6336007.cms>,
it receives a warning letter from USFDA

Sun Pharma subsidiary receives warning letter from USFDA

 MUMBAI | Tue Aug 31, 2010 7:50pm IST

(Reuters) - The U.S. unit of Indian drugmaker Sun Pharmaceutical has
received a warning letter from the United States Food and Drug
Administration (USFDA) after its New Jersey manufacturing plant was
inspected.

Sun plans to respond to the USFDA within 15 days, and the company would work
"cooperatively and expeditiously" to resolve the matters mentioned in the
warning letter, Sun said in a statement, without giving details.

Mumbai-based Sun said the USFDA letter was issued as a follow-up to the
inspection of the manufacturing facility in New Jersey in February, during
which the regulator had identified violations of manufacturing regulations.

The company said it maintained its consolidated sales growth guidance for
the current fiscal year to March 2011. Sun Pharmaceutical had said last
month it expected to meet its guidance of 18-20 percent revenue growth in
2010/11.
(Reporting by Sumeet Chatterjee; Editing by Will Waterman)

http://in.reuters.com/article/idINIndia-51190020100831

-- 
You received this message because you are subscribed to the Google
Groups "Mental Health Advocacy (News 'N Views) India" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to
[email protected]
For more options, visit this group at
http://groups.google.com/group/MhaNewsViewsIndia?hl=en
-------------
Affiliated Groups :  MENTAL HEALTH ADVOCACY INDIA
[email protected]
Discussions on mental health law / policy / plan monitoring / human rights etc 
[email protected]
India-specific news and views related to mental health
[email protected]
Information and support to carers of people with mental health issues
[email protected]
Mutual support and sharing of experiential knowledge, skills and social 
learning amongst peers

Reply via email to